| . | Untreated . | NMV-r Treated a . | |
|---|---|---|---|
| . | Pre–Omicron Era (n = 18 005) . | Omicron Era (n = 12 281) . | Omicron Era (n = 372) . |
| Male | 8882 (49) | 5584 (45) | 161 (43) |
| Age, y, mean (SD) | 40.1 (15.9) | 44.7 (16.9) | 57.6 (14.9) |
| <65 | 16 749 (93) | 10 588 (86) | 246 (66) |
| ≥65 | 1256 (7) | 1693 (14) | 126 (34) |
| Vaccinated: ≥1 SARS-CoV-2 vaccine | 1277 (7.1) | 6593 (54) | 272 (73) |
| Continuous 6-mo medical/pharmacy enrollment b | 5068 (26) | 3479 (28) | 131 (35) |
| High risk within those with 6-mo enrollment b,c | 2415 (48) | 1893 (54) | 96 (73) |
| Hospitalized within 30 d of index date | 154 (0.9) | 92 (0.8) | 1 (0.3) |
| Geographic region | |||
| Northeast | 1754 (10) | 1047 (9) | 46 (12) |
| Midwest | 1939 (11) | 1077 (9) | 13 (4) |
| South | 12 091 (67) | 7735 (63) | 235 (63) |
| West | 1387 (8) | 1897 (15) | 50 (13) |
| Not available | 834 (5) | 525 (4) | 28 (8) |
| . | Untreated . | NMV-r Treated a . | |
|---|---|---|---|
| . | Pre–Omicron Era (n = 18 005) . | Omicron Era (n = 12 281) . | Omicron Era (n = 372) . |
| Male | 8882 (49) | 5584 (45) | 161 (43) |
| Age, y, mean (SD) | 40.1 (15.9) | 44.7 (16.9) | 57.6 (14.9) |
| <65 | 16 749 (93) | 10 588 (86) | 246 (66) |
| ≥65 | 1256 (7) | 1693 (14) | 126 (34) |
| Vaccinated: ≥1 SARS-CoV-2 vaccine | 1277 (7.1) | 6593 (54) | 272 (73) |
| Continuous 6-mo medical/pharmacy enrollment b | 5068 (26) | 3479 (28) | 131 (35) |
| High risk within those with 6-mo enrollment b,c | 2415 (48) | 1893 (54) | 96 (73) |
| Hospitalized within 30 d of index date | 154 (0.9) | 92 (0.8) | 1 (0.3) |
| Geographic region | |||
| Northeast | 1754 (10) | 1047 (9) | 46 (12) |
| Midwest | 1939 (11) | 1077 (9) | 13 (4) |
| South | 12 091 (67) | 7735 (63) | 235 (63) |
| West | 1387 (8) | 1897 (15) | 50 (13) |
| Not available | 834 (5) | 525 (4) | 28 (8) |
Data are presented as No. (%) unless noted otherwise.
Abbreviation: NMV-r, nirmatrelvir/ritonavir.
aExcludes patients treated with other SARS-CoV-2 therapies.
bAllowed for a 30-day gap in coverage.
cHigh-risk status for progression to severe SARS-CoV-2 infection.
| . | Untreated . | NMV-r Treated a . | |
|---|---|---|---|
| . | Pre–Omicron Era (n = 18 005) . | Omicron Era (n = 12 281) . | Omicron Era (n = 372) . |
| Male | 8882 (49) | 5584 (45) | 161 (43) |
| Age, y, mean (SD) | 40.1 (15.9) | 44.7 (16.9) | 57.6 (14.9) |
| <65 | 16 749 (93) | 10 588 (86) | 246 (66) |
| ≥65 | 1256 (7) | 1693 (14) | 126 (34) |
| Vaccinated: ≥1 SARS-CoV-2 vaccine | 1277 (7.1) | 6593 (54) | 272 (73) |
| Continuous 6-mo medical/pharmacy enrollment b | 5068 (26) | 3479 (28) | 131 (35) |
| High risk within those with 6-mo enrollment b,c | 2415 (48) | 1893 (54) | 96 (73) |
| Hospitalized within 30 d of index date | 154 (0.9) | 92 (0.8) | 1 (0.3) |
| Geographic region | |||
| Northeast | 1754 (10) | 1047 (9) | 46 (12) |
| Midwest | 1939 (11) | 1077 (9) | 13 (4) |
| South | 12 091 (67) | 7735 (63) | 235 (63) |
| West | 1387 (8) | 1897 (15) | 50 (13) |
| Not available | 834 (5) | 525 (4) | 28 (8) |
| . | Untreated . | NMV-r Treated a . | |
|---|---|---|---|
| . | Pre–Omicron Era (n = 18 005) . | Omicron Era (n = 12 281) . | Omicron Era (n = 372) . |
| Male | 8882 (49) | 5584 (45) | 161 (43) |
| Age, y, mean (SD) | 40.1 (15.9) | 44.7 (16.9) | 57.6 (14.9) |
| <65 | 16 749 (93) | 10 588 (86) | 246 (66) |
| ≥65 | 1256 (7) | 1693 (14) | 126 (34) |
| Vaccinated: ≥1 SARS-CoV-2 vaccine | 1277 (7.1) | 6593 (54) | 272 (73) |
| Continuous 6-mo medical/pharmacy enrollment b | 5068 (26) | 3479 (28) | 131 (35) |
| High risk within those with 6-mo enrollment b,c | 2415 (48) | 1893 (54) | 96 (73) |
| Hospitalized within 30 d of index date | 154 (0.9) | 92 (0.8) | 1 (0.3) |
| Geographic region | |||
| Northeast | 1754 (10) | 1047 (9) | 46 (12) |
| Midwest | 1939 (11) | 1077 (9) | 13 (4) |
| South | 12 091 (67) | 7735 (63) | 235 (63) |
| West | 1387 (8) | 1897 (15) | 50 (13) |
| Not available | 834 (5) | 525 (4) | 28 (8) |
Data are presented as No. (%) unless noted otherwise.
Abbreviation: NMV-r, nirmatrelvir/ritonavir.
aExcludes patients treated with other SARS-CoV-2 therapies.
bAllowed for a 30-day gap in coverage.
cHigh-risk status for progression to severe SARS-CoV-2 infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
